Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 2

5(50.0%)

Phase 3

3(30.0%)

Phase 4

1(10.0%)

N/A

1(10.0%)

10Total

Phase 2(5)

Phase 3(3)

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT06563245Phase 2Recruiting

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Role: lead

NCT05681260Phase 3Recruiting

Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)

Role: lead

NCT04881838Phase 3Active Not Recruiting

CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL

Role: lead

NCT02405676Phase 2Active Not Recruiting

BNHL-2015 for Children or Adolescents in China

Role: lead

NCT04726501Phase 4Active Not Recruiting

CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma

Role: lead

NCT02845882Phase 3Active Not Recruiting

LBL-2016 for Children or Adolescents in China

Role: lead

NCT07168980Phase 2Recruiting

Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents

Role: lead

NCT02959086Recruiting

Shanghai Epidemiology Study for Adolescents and Children with Cancer

Role: lead

NCT03443128Phase 2Completed

Vinorelbine for Recurrent ALCL-2017

Role: lead

NCT03397953Phase 2Completed

Vinorelbine for Recurrent ACLC

Role: lead

NCT03373656Not ApplicableUnknown

Vaccination for Children of H&O and Their Parents

Role: lead

All 11 trials loaded